Glioblastoma Multiforme
0.300
GeneticVariation
disease
UNIPROT
Macular Dystrophy, Butterfly-Shaped Pigmentary, 2
0.300
Biomarker
disease
CTD_human
Patterned dystrophy of retinal pigment epithelium
0.300
Biomarker
disease
CTD_human
Reduced visual acuity
0.100
Biomarker
phenotype
HPO
Atrophic macular change
0.100
Biomarker
phenotype
HPO
Susceptibility to tuberculosis
0.100
SusceptibilityMutation
phenotype
CLINVAR
Atrophoderma maculatum
0.100
Biomarker
disease
HPO
MALARIA, SUSCEPTIBILITY TO (finding)
0.100
GeneticVariation
disease
CLINVAR
BACTEREMIA, SUSCEPTIBILITY TO, 2
0.100
SusceptibilityMutation
phenotype
CLINVAR
Rod-Cone Dystrophy
0.100
Biomarker
disease
HPO
Hepatitis C
0.010
GeneticVariation
disease
BEFREE
The SNP rs3792323 in MAPKAPK3 associates with the outcome of IFN therapy in patients with HCV genotype 1b.
19208361
2009
Hepatitis C, Chronic
0.010
GeneticVariation
disease
BEFREE
A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C .
19208361
2009
Urticaria
0.010
Biomarker
disease
BEFREE
Our result verified CREB5 biological regulation module in the upstream of frontal cortex of HIVE -control patients (MAPKAPK3 activation; DGKG, LY96, TNFRSF11B inhibition) and downstream (ATP6V0E1, CFB, DGKG, MX1, TGFBR3 activation; LGALS3BP, RASGRP3, RDX, STAT1 inhibition), whereas in the upstream of frontal cortex of HIVE (BST2, CFB, LCAT, TNFRSF11B activation; CFHR1, LY96 inhibition) and downstream (GAS1, LCAT, LGALS3BP, NFAT5, VEZF1, ZNF652 activation; DGKG, IFITM1, LY96, TNFRSF11B inhibition).
21132541
2011
×
CUI:
C0221232
Disease:
Welts
Welts
0.010
Biomarker
phenotype
BEFREE
Our result verified CREB5 biological regulation module in the upstream of frontal cortex of HIVE -control patients (MAPKAPK3 activation; DGKG, LY96, TNFRSF11B inhibition) and downstream (ATP6V0E1, CFB, DGKG, MX1, TGFBR3 activation; LGALS3BP, RASGRP3, RDX, STAT1 inhibition), whereas in the upstream of frontal cortex of HIVE (BST2, CFB, LCAT, TNFRSF11B activation; CFHR1, LY96 inhibition) and downstream (GAS1, LCAT, LGALS3BP, NFAT5, VEZF1, ZNF652 activation; DGKG, IFITM1, LY96, TNFRSF11B inhibition).
21132541
2011
MACULAR DYSTROPHY, PATTERNED, 3
0.510
GermlineCausalMutation
disease
ORPHANET
A dominant mutation in MAPKAPK3, an actor of p38 signaling pathway, causes a new retinal dystrophy involving Bruch's membrane and retinal pigment epithelium.
26744326
2016
MACULAR DYSTROPHY, PATTERNED, 3
0.510
GeneticVariation
disease
UNIPROT
A dominant mutation in MAPKAPK3, an actor of p38 signaling pathway, causes a new retinal dystrophy involving Bruch's membrane and retinal pigment epithelium.
26744326
2016
Retinal Diseases
0.010
GeneticVariation
group
BEFREE
In conclusion, we identified the first pathogenic mutation in MAPKAPK3 associated with a retinal disease .
26744326
2016
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
0.010
Biomarker
disease
BEFREE
Inhibition of MAPKAPK3 impedes PDAC growth, identifying a potential new kinase target in PDAC .
26988419
2016
MACULAR DYSTROPHY, PATTERNED, 3
0.510
Biomarker
disease
BEFREE
The natural history of MCRPE is in relation to the role of MAPKAPK3 in BM modeling, vascular endothelial growth factor activity, retinal pigment epithelial responses to aging, and oxidative stress.
27474146
2016
Colorectal Carcinoma
0.010
Biomarker
disease
BEFREE
However, for colorectal cancer we present the detection of four tumor-associated antigen (TAA) biomarkers (MAPKAPK3 , PIM-1, STK4, and GTF2B) as possible TAA targets for autoantibody production.
31309477
2019
Malignant neoplasm of colon and/or rectum
0.010
Biomarker
disease
BEFREE
However, for colorectal cancer we present the detection of four tumor-associated antigen (TAA) biomarkers (MAPKAPK3 , PIM-1, STK4, and GTF2B) as possible TAA targets for autoantibody production.
31309477
2019